The company’s nanowire technology is protected by 14 patents licensed from Harvard University, plus additional NanoDx™ patents and patents pending. Nanosensor-compatible semiconductor technology is used under license from IBM Research.
The NanoDx™ Tbit™ System has been granted Breakthrough Device Designation by the FDA, allowing greater and more frequent access to FDA and accelerating our path to FDA clearance.
A key advantage of the NanoDx™ System is its support for rapid application development of new assays. Our product development strategy is focused on a range of potential future applications.
NanoDx™ is headquartered in Southborough, Massachusetts, with biosensor development in Cambridge, Massachusetts, and assay development and manufacturing in Albuquerque, New Mexico.
*The NanoDx™ System has not been evaluated by the FDA or other regulatory agencies.
